Improving safety of cancer immunotherapy via delivery technology.

Published on Jan 1, 2021in Biomaterials10.317
· DOI :10.1016/J.BIOMATERIALS.2020.120407
Doudou Hu2
Estimated H-index: 2
(ZJU: Zhejiang University),
Wei Zhang20
Estimated H-index: 20
(ZJU: Zhejiang University)
+ 3 AuthorsYouqing Shen63
Estimated H-index: 63
(ZJU: Zhejiang University)
Sources
Abstract
Abstract Breakthroughs in molecular mechanisms underlying immune-suppressive tumor microenvironment and paradigm shifts in the cancer-immunity response cycle have profoundly changed the landscape of cancer immunotherapy. However, one of the challenges is to mitigate the serious side effects caused by systemic autoimmunity and autoinflammatory responses following immunotherapy. Thus, restraining the activation of the immune system in healthy tissues is highly desirable to address this problem. Bioengineering and delivery technologies provide a solution to the issue. In this Review, we first introduce immune-related adverse effects of main immunotherapies and the underlying mechanisms, summarize various strategies to construct bioengineering and delivery systems in order to reduce their immunotoxicities, and highlight the importance for the development of immunotoxicity-related animal models.
📖 Papers frequently viewed together
5 Citations
1 Citations
11 Citations
References174
Newest
#1Ningning Wang (SDU: Shandong University)H-Index: 3
#2Yaxin Zhou (SDU: Shandong University)H-Index: 2
Last. Yuxia Luan (SDU: Shandong University)H-Index: 29
view all 8 authors...
Abstract Immune checkpoint blockade (ICB) strategy based on suppressing programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway has been proved to be promising and effective in cancer immunotherapy. However, its potential risk of immune-related adverse events (irAEs) places stringent requirements on the precise loading of anti-PD-L1 agent in nanomedicine. Precise control of the loading content of anti-PD-L1 antibody is a difficult task since physical encapsulation has inevitable draw...
5 CitationsSource
#1Binfan Chen (CAS: Chinese Academy of Sciences)H-Index: 7
#2Ang Gao (CAS: Chinese Academy of Sciences)H-Index: 17
Last. Yongzhuo HuangH-Index: 32
view all 10 authors...
Abstract Tumor microenvironment (TME) closely affects cancer progression by promoting cancer cell survival and proliferation, drug resistance, metastasis, and immunosuppression as well. Remodeling TME is a promising therapeutic strategy for anticancer. mTOR signaling is an essential regulator for cellular metabolism and tumor-associated macrophages (TAMs) repolarization. There is an integrated crosstalk among mTOR/metabolism/immunity. Angiogenesis can also regulate metabolism and immunity. Based...
8 CitationsSource
#1Jiyoon Bu (UW: University of Wisconsin-Madison)H-Index: 8
#1Jiyoon Bu (UW: University of Wisconsin-Madison)H-Index: 5
Last. Seungpyo Hong (UW: University of Wisconsin-Madison)H-Index: 36
view all 10 authors...
Upregulation of programmed death ligand 1 (PD-L1) allows cancer cells to evade antitumor immunity. Despite tremendous efforts in developing PD-1/PD-L1 immune checkpoint inhibitors (ICIs), clinical ...
7 CitationsSource
#1Adi Diab (University of Texas MD Anderson Cancer Center)H-Index: 32
#2Nizar M. Tannir (University of Texas MD Anderson Cancer Center)H-Index: 57
Last. Daniel C. Cho (NYU: New York University)H-Index: 17
view all 23 authors...
This single-arm, phase I dose-escalation trial (NCT02983045) evaluated bempeg­a­ldesleukin (NKTR-214/BEMPEG), a CD122-preferential IL2 pathway agonist, plus nivolumab in 38 patients with selected immunotherapy-naive advanced solid tumors (melanoma, renal cell carcinoma, and non–small cell lung cancer). Three dose-limiting toxicities were reported in 2 of 17 patients during dose escalation [hypotension (n = 1), hyperglycemia (n = 1), metabolic acidosis (n = 1)]. The most common treatment-related ...
38 CitationsSource
#1Feihu Wang (Johns Hopkins University)H-Index: 20
#2Dongqing Xu (Johns Hopkins University)H-Index: 2
Last. Honggang Cui (Johns Hopkins University)H-Index: 45
view all 14 authors...
Immune checkpoint blockers (ICBs) have shown great promise at harnessing immune system to combat cancer. However, only a fraction of patients can directly benefit from the anti–programmed cell death protein 1 (aPD1) therapy, and the treatment often leads to immune-related adverse effects. In this context, we developed a prodrug hydrogelator for local delivery of ICBs to boost the host’s immune system against tumor. We found that this carrier-free therapeutic system can serve as a reservoir for e...
18 CitationsSource
#1Zhaoting Li (CPU: China Pharmaceutical University)H-Index: 4
#2Yixin Wang (CPU: China Pharmaceutical University)H-Index: 6
Last. Minjie Sun (CPU: China Pharmaceutical University)H-Index: 25
view all 6 authors...
Anti–programmed cell death 1 ligand 1 (PD-L1) therapy is extraordinarily effective in select patients with cancer. However, insufficient lymphocytic infiltration, weak T cell–induced inflammation, and immunosuppressive cell accumulation in the tumor microenvironment (TME) may greatly diminish the efficacy. Here, we report development of the FX@HP nanocomplex composed of fluorinated polymerized CXCR4 antagonism (FX) and paclitaxel-loaded human serum albumin (HP) for pulmonary delivery of anti–PD-...
20 CitationsSource
#1Di-Wei Zheng (WHU: Wuhan University)H-Index: 19
#2Fan Gao (WHU: Wuhan University)H-Index: 14
Last. Xian-Zheng Zhang (WHU: Wuhan University)H-Index: 73
view all 10 authors...
The unsatisfactory response rate of immune checkpoint blockade (ICB) immunotherapy severely limits its clinical application as a tumor therapy. Here, we generate a vaccine-based nanosystem by integrating siRNA for Cd274 into the commercial human papillomavirus (HPV) L1 (HPV16 L1) protein. This nanosystem has good biosafety and enhances the therapeutic response rate of anti-tumor immunotherapy. The HPV16 L1 protein activates innate immunity through the type I interferon pathway and exhibits an ef...
7 CitationsSource
#1Aslan Mansurov (U of C: University of Chicago)H-Index: 6
#2Jun Ishihara (U of C: University of Chicago)H-Index: 11
Last. Jeffrey A. Hubbell (U of C: University of Chicago)H-Index: 115
view all 12 authors...
Checkpoint-inhibitor (CPI) immunotherapy has achieved remarkable clinical success, yet its efficacy in ‘immunologically cold’ tumours has been modest. Interleukin-12 (IL-12) is a powerful cytokine that activates the innate and adaptive arms of the immune system; however, the administration of IL-12 has been associated with immune-related adverse events. Here we show that, after intravenous administration of a collagen-binding domain fused to IL-12 (CBD–IL-12) in mice bearing aggressive mouse tum...
25 CitationsSource
#1Dominik Marschner (University of Freiburg)H-Index: 1
#2Martina Falk (University of Freiburg)H-Index: 2
Last. Natalie Köhler (Stanford University)H-Index: 3
view all 20 authors...
Immune checkpoint inhibitor (ICI) therapy has shown a significant benefit in the treatment of a variety of cancer entities. However, immune-related adverse events (irAEs) occur frequently and can lead to ICI treatment termination. MicroRNA-146a (miR-146a) has regulatory functions in immune cells. We observed that mice lacking miR-146a developed significantly more severe irAEs compared to wildtype mice in several irAE target organs in two different murine models. MiR-146a-/- mice exhibited increa...
9 CitationsSource
#1Lucy Boyce Kennedy (Duke University)H-Index: 2
#2April K. S. Salama (Duke University)H-Index: 28
Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy, manipulate the immune system to recognize and attack cancer cells. These therapies have the potential to induce durable responses in multiple solid and hematologic malignancies and thus have transformed treatment algorithms for numerous tumor types. Cancer immunotherapies lead to unique toxicity profiles distinct from the toxicities of other cancer therapies, depending on their mechanism of action. These toxicitie...
93 CitationsSource
Cited By3
Newest
#1Minsu Kwon (KU: Korea University)
#2Hanul Jung (KU: Korea University)
Last. In-San Kim (Kigali Institute of Science and Technology)H-Index: 60
view all 4 authors...
Abstract Cancer immunotherapy (CI) represented by immune checkpoint inhibitors (ICIs) presents a new paradigm for cancer treatment. However, the types of cancer that attain a therapeutic benefit from ICIs are limited, and the efficacy of these treatments does not meet expectations. To date, research on ICIs has mainly focused on identifying biomarkers and patient characteristics that can enhance the therapeutic effect on tumors. However, studies on combinational strategies for CI are being activ...
Source
#1Shu-Lan Li (WHU: Wuhan University)H-Index: 3
#2Peng Jiang (WHU: Wuhan University)H-Index: 5
Last. Yi Liu (WHU: Wuhan University)H-Index: 52
view all 4 authors...
Source
#1Hui Tang (Peking Union Medical College Hospital)
#2Jianfeng Zhou (Peking Union Medical College Hospital)
Last. Chunmei Bai (Peking Union Medical College Hospital)H-Index: 7
view all 3 authors...
Immune checkpoint inhibitor (ICI) is a revolutionary breakthrough in the field of cancer treatment. Because of dysregulated activation of the immune system, patients with autoimmune disease (AID) are usually excluded from ICI clinical trials. Due to a large number of cancer patients with preexisting AID, the safety and efficacy of ICIs in these patients deserve more attention. This review summarizes and analyzes the data regarding ICI therapy in cancer patients with preexisting AID from 17 publi...
1 CitationsSource